Oncology Xagena
An investigational new drug Sutent ( Sunitinib ) more than doubled survival and significantly reduced tumor growth and spread in patients with Imatinib-resistant gastrointestinal stromal tumors ( GIS ...
A study suggests that Sunitinib ( Sutent ) is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options. The study is published ...
Sunitinib ( Sutent ) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma ...
Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...
Treatment with Everolimus ( Certican ) prolongs progression-free survival relative to placebo in patients with metastatic kidney cancer ( renal cell carcinoma ) who have experienced treatment failur ...
Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...
Sunitinib ( Sutent ) prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer ( metastatic renal cell carcinoma ) patients with a poor prognosis such as ...
The safety and maximum tolerated dose ( MTD ) of Sunitinib malate( Sutent ) in combination with Bevacizumab ( Avastin ) has been assessed in patients with metastatic renal cell carcinoma ( mRCC ) in a ...
Antiangiogenic agents Sunitinib ( Sutent ) and Pazopanib ( Votrient ) are SOC ( standard of care ) for metastatic renal cell carcinoma ( mRCC ), but new therapies are needed as patients advance throug ...
An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor ( FGF ) pathway activation ha ...
Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. A phase II trial assessed the antitumor activity ...
Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. A phase II trial has assessed the antitumor acti ...
Results from the phase 3 CheckMate -214 trial evaluating Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) versus Sunitinib ( Sutent ) in patients with previously untreated advanced or metastatic renal ...
Radical metastasectomy followed by observation is a commonly used strategy in selected patients with metastatic renal cell carcinoma ( mRCC ). RESORT was the largest prospective study that assesse ...
The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta ), tyrosine kinase inhibitor, met both primary endpoints of ...
